Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Short-term Investments (2016 - 2025)

CorMedix's Short-term Investments history spans 10 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 66.53% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, down 66.53%, while the annual FY2025 figure was $3.7 million, 66.53% down from the prior year.
  • Short-term Investments for Q4 2025 was $3.7 million at CorMedix, down from $7.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $31.4 million in Q2 2025 and bottomed at $75540.0 in Q1 2024.
  • The 5-year median for Short-term Investments is $5.3 million (2021), against an average of $7.3 million.
  • The largest annual shift saw Short-term Investments soared 28166.01% in 2021 before it crashed 99.45% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $12.1 million in 2021, then crashed by 98.98% to $124102.0 in 2022, then fell by 29.87% to $87037.0 in 2023, then skyrocketed by 12580.81% to $11.0 million in 2024, then plummeted by 66.53% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Short-term Investments are $3.7 million (Q4 2025), $7.2 million (Q3 2025), and $31.4 million (Q2 2025).